ArticleJournal of the American Heart Association2023
Subclinical Cardiovascular Disease in US Adults With and Without Diabetes.
Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Differences in natriuretic peptide response in self-identified white and black individuals: a physiological clinical trial.Nature communications · 2025Trial
- Association of high-sensitivity cardiac troponin T with all-cause and cardiovascular mortality in a mobile cohort of older adults aged 70 to 95 years - Results from the AugUR study.American journal of preventive cardiology · 2026Article
- Associations of High-Sensitivity Cardiac Troponin and N-Terminal Pro-B-Type Natriuretic Peptide With Echocardiographic Features in Patients With Hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- The role of COPD and inhaled corticosteroids in major adverse cardiovascular events in cardiovascular-kidney-metabolic populations.BMC medicine · 2026Article
- Associations of High-Sensitivity Cardiac Troponin T, D-Dimer, and N-Terminal Pro-B-Type Natriuretic Peptide with Subclinical Cardiovascular Dysfunction in the General Population: A Retrospective Cross-Sectional Study.Vascular health and risk management · 2026Article
- Saudi Heart Association Scientific Statement on Cardiovascular-Kidney-Liver-Metabolic (CKLM) Syndrome.Journal of the Saudi Heart Association · 2026Article
- Periodontitis, subclinical myocardial injury, and cardiovascular mortality among US adults: a population-based study.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Association of plant-based diets with subclinical cardiovascular disease in U.S. adults, 1999-2004.American journal of preventive cardiology · 2025Article
- Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025Review
- Associations of cardiac biomarkers with chronic kidney disease and mortality in US individuals without prevalent cardiovascular disease.Scientific reports · 2025Article
- N-terminal Pro-B-Type Natriuretic Peptide and Risk for Diabetes Mellitus and Metabolic Syndrome.The Journal of clinical endocrinology and metabolism · 2025Article
- Associations Between Lead and Cadmium Exposure and Subclinical Cardiovascular Disease in U.S. Adults.Cardiovascular toxicology · 2025Article
- Associations of triglyceride-glucose index with N-terminal pro-B-type natriuretic peptide and mortality in middle-aged and elderly individuals.Frontiers in endocrinology · 2025Article
- Non-HDL-C/HDL-C Ratio and N-Terminal Pro-B-Type Natriuretic Peptide in the general and hospital-based population: a cross-sectional validation study.Frontiers in endocrinology · 2025Article
- Glycated Hemoglobin and Cardiovascular Disease in Patients Without Diabetes.Journal of clinical medicine · 2024Review
- Relationship of Subendocardial Perfusion to Myocardial Injury, Cardiac Structure, and Clinical Outcomes Among Patients With Hypertension.Circulation · 2024Observational
- The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects-A Family Doctor Perspective.Journal of clinical medicine · 2024Review
- Elevated cardiac biomarkers in relatively healthy U.S. adults.European journal of internal medicine · 2024Article
- Associations of elevated cardiac biomarkers with hyperuricemia and mortality in US adults without prevalent cardiovascular disease.Frontiers in endocrinology · 2024Article
- The essential role of dual-energy x-ray absorptiometry in the prediction of subclinical cardiovascular disease.Frontiers in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Background We characterized the burden and prognostic value of subclinical cardiovascular disease (CVD) assessed by cardiac biomarkers among adults with and without diabetes in the general US population. Methods and Results We measured hs-cTnT (high-sensitivity cardiac troponin T) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) in stored serum samples from the 1999 to 2004 National Health and Nutrition Examination Survey. Among US adults without a history of CVD (n=10 304), we estimated the prevalence of elevated hs-cTnT (≥14 ng/L) and NT-proBNP (≥125 pg/mL) in those with and without diabetes. We examined the associations between elevated hs-cTnT and NT-proBNP with all-cause and CVD mortality after adjustment for demographics and traditional CVD risk factors. The crude prevalence of subclinical CVD (elevated hs-cTnT or NT-proBNP) was ≈2 times higher in adults with (versus without) diabetes (33.4% versus 16.1%). After age adjustment, elevated hs-cTnT, but not elevated NT-proBNP, was more common in those with diabetes, overall and across age, sex, race and ethnicity, and weight status. The prevalence of elevated hs-cTnT was significantly higher in those with longer diabetes duration and worse glycemic control. In persons with diabetes, elevated hs-cTnT and NT-proBNP were independently associated with all-cause mortality (adjusted hazard ratio [HR], 1.77 [95% CI, 1.33-2.34] and HR, 1.78 [95% CI, 1.26-2.51]) and CVD mortality (adjusted HR, 1.54 [95% CI, 0.83-2.85] and HR, 2.46 [95% CI, 1.31-4.60]). Conclusions Subclinical CVD affects ≈1 in 3 US adults with diabetes and confers substantial risk for mortality. Routine testing of cardiac biomarkers may be useful for assessing and monitoring risk in persons with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.